Forbes January 2, 2025
Howard Gleckman

President-elect Donald Trump prides himself on making deals. Here is one for him: Keep Joe Biden’s commitment to have Medicare pay for GLP-1 drugs such as Ozempic and Wegovy for weight loss. But only if the drugmakers agree to substantially reduce their prices right away.

Such a move would be fraught for Trump and his Republican allies on multiple levels. But it presents the incoming president with a major political opportunity as well as some significant challenges. And not doing the deal brings its own risks.

The Backstory

While Medicare pays for the GLP-1 drugs for people with Type-2 diabetes and some forms of heart disease, it has been barred by an old federal law from paying for weight-loss drugs....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma / Biotech
Where Medicaid cuts stand
Will Congress’s new AI plan survive Trump?
Black Book Finds Tariff Pressures Driving Reshoring of U.S. Healthcare Manufacturing
Trump administration announces new tariff plan
ACA enrollment increase driven by growth in states won by Trump: KFF

Share This Article